Advanced Elastography for Hepatology
Enhance your hepatology workflow with precise, guided measurements. Elastography Australia provides stronger performance in challenging cases, comprehensive reporting, and the ability to monitor fibrosis progression with confidence, aligning with GESA guidelines for MAFLD.
Challenges We Solve
We understand your challenges
Obese Patient Challenge
Traditional blind devices struggle with high-BMI patients, leading to failed scans in the cohort that most often needs fibrosis staging.
Accuracy Concerns
Without imaging guidance, you cannot confirm measurement location or avoid vessels, which matters in borderline and longitudinal cases.
Equipment Costs
Current devices can be expensive and require multiple probes, increasing both capital and ongoing operating costs.
Efficiency Pressure
Lengthy scan times and failed measurements create bottlenecks in high-demand hepatology clinics.
Treatment Monitoring
Tracking fibrosis changes over time requires reliable, reproducible measurements and transparent limitations.
Report Quality
Referring physicians need a clear clinical report, not a single isolated number without context.
Seamless Integration
Fits your clinical workflow
Initial Fibrosis Assessment
Structured liver evaluation for new hepatology referrals and patients with suspected advanced fibrosis.
- 1Review history, laboratory work, and prior imaging before the scan.
- 2Position the probe with real-time visual guidance to avoid non-target anatomy.
- 3Acquire multiple validated measurements and assess quality metrics.
- 4Interpret LSM and attenuation outputs in the context of the clinical picture.
- 5Use results to guide referral, surveillance, or further investigation decisions.
Treatment Response Monitoring
Track fibrosis and steatosis trends during antiviral, metabolic, or lifestyle intervention.
- 1Establish a reliable baseline before treatment or major intervention.
- 2Schedule serial assessments at clinically appropriate intervals.
- 3Compare values with consistent technique and documented scan quality.
- 4Correlate change with biochemistry and symptom progression.
- 5Escalate to biopsy or advanced imaging only when clinically required.
Return on Investment
The business case is clear
Large published NAFLD FibroTouch cohort; M vs XL matters for TE comparators
Median exam time versus 47 seconds for FibroScan in comparative data
Typically modestly lower capital than comparable new FibroScan; confirm with a written quote
Key ROI Factors
More scans completed across a busy clinic day.
Guided placement reduces technical failures and wasted appointments.
No S, M, and XL switching during clinic sessions.
Supports honest case selection, especially where ascites is present.
Useful in studies and longitudinal fibrosis monitoring workflows.
Real-time imaging improves operator confidence in measurement position. AUROC of 0.83 for significant fibrosis and 0.84 for advanced fibrosis.
Ready to transform your practice?
Join leading Australian clinicians who have already made the switch to guided liver elastography.